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Urinary CD4+ T cells identify SLE patients with proliferative Lupus nephritis and can 
be used to monitor treatment response  
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Gollasch M, Schneider U, Aupperle K,  Humrich JY, Hiepe F, Backhaus M, Radbruch A, 
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Abstract 
Objectives: Proliferative lupus nephritis (LN) is one of the major concerns in the treatment of 
systemic lupus erythematosus (SLE). Here we evaluate urinary CD4+ T cells as a biomarker 
of active LN and indicator of treatment response.   
Methods: Urinary CD3+CD4+ T cells were quantified using flow cytometry in 186 urine 
samples from 147 SLE patients. 14 patients were monitored as follow up. 31 patients with 
other nephropathies and 20 healthy volunteers were included as controls. 
Results: In SLE urinary CD4+ T cell counts ≥800/100ml were observed exclusively in 
patients with active LN. ROC analysis documented clear separation of SLE patients with 
active and non-active LN (area under the curve 0.9969). All patients with contemporary 
kidney biopsy showing proliferative LN presented high urinary CD4+ numbers. In patients 
monitored under therapy a normalisation of urinary CD4+ T cell counts indicated lower 
disease activity and better renal function. In contrast, patients with persistence or increase of 
urinary T cells displayed worse outcomes.  
Conclusions: Urinary CD4+ T cells are a highly sensitive and specific marker to detect 
proliferative LN in SLE patients. Furthermore, monitoring urinary CD4+ T cells may help 
identify treatment responders and treatment failure and enable patient tailored therapy in the 
future. 
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Introduction 
Lupus nephritis (LN) is one of the most common manifestations of systemic lupus 
erythematosus (SLE) and implies a significant risk for the patient.[1] Despite advances in the 
treatment of LN, the occurrence of nephritis is still associated with a relevant burden of 
morbidity and mortality.[2] The patient is threatened from two sides: undertreatment, 
implicating uncontrolled autoimmunity, and overtreatment, resulting in toxicity and danger of 
serious infections.[3] 
The diagnosis of LN is usually suspected in patients with systemic signs of SLE 
activity and urinary abnormalities, and is confirmed by kidney biopsy. The sooner the 
diagnosis of LN is established the better is the prognosis.[4-6] However, urinary findings may 
be misleading or unspecifically elevated, while kidney biopsy is an invasive procedure not 
free of risk.[7] 
An ideal biomarker would non-invasively identify patients with acute LN and 
quantitatively reflect the inflammation in the kidneys to allow monitoring of the disease and 
patient tailored treatment. We hypothesize that a SLE marker specific for LN would most 
likely be found in urine. Additionally, we expect the sensitivity of such a marker to be a 
function of its involvement in the pathogenesis of LN, thus a marker that reflects an 
indispensable key event in the local pathogenesis is likely to be sensitive for the underlying 
disease. 
Using flow cytometry based analysis of cells that are considered crucial in the 
pathogenesis of SLE has yielded valuable biomarkers. Quantification of plasmablasts in the 
peripheral blood as well as assessing the expression of interferon induced markers on 
monocytes both correlate closely with disease activity in lupus patients.[8, 9] In our previous 
work we have reported that CD4+ T cells can be found in abundance in the urine of patients 
with active LN. The CD4+ T cells in the urine and in kidney biopsies were enriched for 
CXCR3 expressing cells compared to the blood, suggesting CXCR3 mediated recruitment of 
CD4+ T cells into the kidney.[10] Importantly, the amount of urinary CD4+ T cells in SLE 
patients correlated with active renal involvement, suggesting urinary T cells as a potential 
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biomarker for LN.[10] Meanwhile these results have been confirmed by another group,[11] 
however a larger trial on T cells as biomarker for LN is still missing.  
Infiltration of inflammatory cells into the kidneys is a well established element of LN, 
particularly the proliferative forms.[12-14] This infiltration predominantly consists of CD4+ T 
cells,[15, 16] and the extent of the infiltrate is one of the best predictors of renal outcome.[12-14] 
The phenotype of the CD4+ T cells in the urine is qualitatively reminiscent of the renal 
infiltrating cells rather than the T cells circulating in the peripheral blood.[10] Hence, the 
assumption that the CD4+ T cells found in the urine originate from the inflamed kidney 
interstitium is reasonable, and strengthened by the observed close correlation with LN 
activity.  
In the present study we analyzed a large cross sectional cohort of SLE patients, with 
and without renal involvement, for the presence of urinary CD4+ T cells. Patients with other 
nephropathies and healthy volunteers were analyzed as a control group. Furthermore, a 
cohort of patients with LN was monitored under treatment in the follow up. 
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Patients and Methods 
Patients  
We collected and analyzed 186 samples from 147 SLE patients.  36 SLE patients 
were measured more than once; 19 of these 30 patients were measured twice, 3 Patients 
were analysed three times, the respective measurements were all seperated by at least 12 
month; these data sets were included in all analyses (Figs 1-5). 14 SLE patients were 
monitored at shorter intervals and these follow up measurements were only included in the 
data set presented in Figure 6. 4 further patients with SLE were analyzed in whom the kidney 
biopsy revealed a non-SLE related nephropathy. These 4 patients were only included in the 
correlation with histology and the ROC analysis (Fig 3 and 4). For all Patients the Systemic 
Lupus Erythematosus Disease Activity Index (SLEDAI) was calculated, a score system 
containing 24 items reflecting the disease activity. Patients with a SLEDAI ≥10 were 
considered to have severely active SLE disease; patients with a SLEDAI <10 were 
considered inactive to moderately active. 104 of these samples were taken from SLE 
patients with past or present involvement of the kidneys, 64 samples were obtained from 
SLE patients without any signs or history of renal affection. 
The patient group with active SLE and past or present renal involvement contains 
patients with active nephritis, but not exclusively (n = 104). Active nephritis was defined by 
current renal biopsy demonstrating LN; in absence of a current biopsy, active LN was defined 
as SLEDAI ≥10 and at least two renal elements of the SLEDAI (n = 29). 
Proliferative/inflammatory nephritis was defined as patients with active nephritis, except 
cases of biopsy proven pure class I or V nephritis (n = 26).  
Of 29 Patients defined as active LN, 25 had an active biopsy showing LN, 4 were 
defined over the SLEDAI and rSLEDAI. Two of these 4 patients had prior kidney biopsy and 
now presented with worsening kidney function and increasing proteinuria. One further patient 
had active SLE disease with newly onset proteinuria, erythrocyteuria and urinary casts, but 
was not biopsied. One patient had increasing creatinine values, newly onset proteinuria and 
erythrocyteuria combined with active SLE, however without undergoing kidney biopsy. 
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For all patients with active disease, the renal SLEDAI (rSLEDAI) was determined by 
adding up the renal features of the regular SLEDAI (proteinuria, erythrocyteuria, 
leucocyteuria, casts). In cases without documented sediment the feature casts was omitted. 
Kidney biopsy was judged as being current if it had been undertaken ≤4 weeks apart from 
urine analysis. 
31 patients with other nephropathies and 20 healthy volunteers were included as a 
control group. The 31 patients with other nephropathies consisted of 13 patients with diabetic 
nephropathy, 10 patients with ANCA associated vasculitis and 8 patients with different 
proteinuric syndromes (1x cast nephropathy, 1x renal amyloidosis, 1x minimal change, 2x 
focal segmental glomerulosclerosis, 1x global glomerulosclerosis, 2x membranous 
glomerulonephritis).  All patients provided personal consent to participate in our study for 
research purposes. Samples were collected between 2006-2012 from patients of the 
Departments of Rheumatology and Clinical Immunology, Nephrology and Intensive Care 
Medicine, Charité University Hospital, Berlin, Germany. Patients from our initially reported 
cohort were reanalyzed for clinical data not previously provided and included in the present 
study.  
The study was approved by the ethics committee of the Charité University Hospital 
(Charité EA1/034/10) and was conducted according to the ethical guidelines at our institution 
and the Helsinki Declaration. 
 
Sample preparation and flow cytometry 
Urine samples were collected, immediately centrifuged and washed with PBS/BSA. 
The median sample size was 100ml urine. The usual standing time for the urine was 4-6 h; 
urine samples from the previous day were discarded. Cells were stained with anti-hCD3-PE 
(clone UCHT-1 DRFZ, Berlin, Germany or clone HIT3a Biolegend, San Diego, USA), anti-
hCD4-FITC (clone TT1 DRFZ, Berlin, Germany or OKT4 Biolegend, San Diego, USA). To 
block unspecific binding, cells were stained in PBS/BSA containing 10% human IgG 
(Flebogamma, Grifols, Langen, Germany); to exclude dead cells, propidium iodide (Sigma-
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Aldrich, Germany) was immediately added prior to flow cytometry. To calculate cell numbers, 
the entire samples were acquired and the amount of cells was normalized as cells per 100ml 
initial urine sample. The cells were analyzed using a Calibur flow cytometer (BD Pharmingen, 
Heidelberg, Germany). Data were analyzed using Flowjo Software (Tree Star, Ashland, 
USA). 
 
Routine laboratory values 
Values for creatinine, urinary sediment, proteinuria, erythrocyte-/haemoglobinuria and 
leucoyteuria were all retrieved from the medical records. Creatinine was measured by the 
Jaffe reaction, 24 h urinary protein excretion using a turbimetric assay. Spot proteinuria, 
erythrocyte-/haemoglobinuria and leucoyteuria were determined using a dipstick assay (Bayer 
Diagnostics, Germany). Urinary sediments were analyzed by trained nephrologists after 
centrifugation of fresh urine. 
 
Statistics 
Medians, Mann-Whitney tests, Spearman correlations and the ROC curve were 
calculated using Graphpad Prism 3.0 (GraphPad Software, San Diego, USA). 
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Results 
Elevated amounts of urinary CD4+ T cells are observed in patients with active LN 
Urine samples from 143 patients with SLE were monitored for the presence of CD4+ 
T cells, 25 repeated measurement separated by at least 12 month were included (n = 168, 
patient characteristic are given in Table 1). In patients with past or present renal involvement 
the number of urinary CD4+ T cells clearly correlated with the disease activity (p < 0.0001, 
Spearman r = 0.5987, n = 104), while in patients with no renal involvement no significant 
correlation was observed (p = 0.2114, Spearman r = 0.2174, n = 64) (Figure 1B). 
In patients with known renal involvement and severely active disease (SLEDAI ≥10) a 
median of 2437 CD4+ T cells/100ml urine were detectable (n = 32). This number of CD4+ T 
cells in the urine was significantly higher in SLE patients with active disease and renal 
involvement compared to the other SLE patients or healthy controls (p < 0.0001). In patients 
with known previous renal involvement but only low to moderate disease activity (SLEDAI 
<10), a median of 29 CD4+ T cells/100ml were found, which was not significantly more than 
the cell counts in SLE patients without renal disease (p = 0.1155). In SLE patients with no 
past or present renal involvement, regardless of the disease activity (SLEDAI 0-15), we 
found only low amounts of CD4+ T cells (median 19 CD4+ T cells/100ml, n = 64). In healthy 
controls the urine was almost devoid of CD4+ T cells (median 3/100ml, n = 20), which was 
significantly fewer cells than the amounts observed in SLE patients, regardless of disease 
activity or renal involvement (p = 0.0003 and p = 0.0074 comparing healthy controls to 
patients with inactive LN and SLE patients without renal involvement, respectively) (Figure 
1C).  
CD4+ T cells numbers of 800/100ml or higher were exclusively found in SLE patients 
with active disease and renal involvement, however not all of these patients had elevated 
urinary T cell counts. To assess which patients with active disease and past or present renal 
affection presented high urinary T cells numbers, and which did not, the number of urinary 
cells in the active patients was correlated with the renal SLEDAI (rSLEDAI). The rSLEDAI 
significantly correlated with the amount of urinary CD4+ T cells (p = 0.0171, Spearman r = 
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0.4185, n = 32). Patients with active disease and low urinary CD4+ T cell counts (<800/100ml) all 
had a relatively low rSLEDAI (0-8), while the patients with elevated T cell counts had higher 
rSLEDAIs (4-16) (Figure 1D). 
 
 
Table 1. Characteristics and medication of patients. Shown are the data form 143 SLE 
patients, the characteristic of the 22 patients measured on several occasions seperated by at 
least 12 month are included (n = 168).  Furthermore the characteristics of the 31 patients 
with other nephropathies and 20 healthy controls are displayed. Abbreviations: Pred - 
Prednisolone, Cyc - pulse cyclophosphamide, MMF - mycophenolate mofetil, Aza - 
azathioprine, MTX - methotrexate, HCQ - hydrochloroquine, CyA – Ciclosporine A, Rtx - 
Rituximab, Dox – Doxorubicin, Borte – Bortezomib,  np – not performed, na - not applicable.  
 
Urinary CD4+ T cell counts correlate with plasma creatinine, proteinuria and 
erythrocyte-/haemoglobinuria but not with leucocyteuria  
Urinary CD4+ T cell numbers correlated with kidney function, assessed by plasma 
creatinine (p = 0.0007, Spearman r = 0.2685, n = 157). The amount number of urinary CD4+ T 
cells also correlated with proteinuria (p < 0.0001, Spearman r = 0.3883, n = 141) and 
erythrocyte-/haemoglobinuria (p < 0.0001, Spearman r = 0.5397, n = 153). Notably, high urinary 
CD4+ T cell counts were also observed in patients without the presence of erythrocytes or 
haemoglobin in the urine, excluding bleeding as the main source of the T cells in urine. No 
correlation was found between the presence of T cells and leucocyteuria (p = 0.4468, Spearman 
r = 0.0629, n = 153) (Figure 2). 
A urine sediment was documented in 14 patients with active SLE and renal involvement. 
All of these patients had urinary CD4+ T cell counts >800/100ml. 5 of these patients had an 
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active sediment, 5 had inconclusive sediments with dysmorphic erythrocytes in insignificant 
numbers and no casts, and 4 had non-nephritic sediment. 12 of these patients (5 with active 
sediment, 3 inconclusive, 4 non-nephritic) had received kidney biopsy in parallel, demonstrating 
proliferative LN. 
 
Elevated numbers of urinary T cells identify patients with proliferative LN  
29 SLE patients undergoing kidney biopsy were analyzed in parallel. All patients with 
type IV LN or a combination of IV and V presented high urinary T cell numbers (n = 20). 
Similarly, two patients with atypical inflammatory LN (one extracapillary, proliferative necrotizing 
glomerulonephritis, one Pauci immune with interstitial lymphocytic nephritis) exhibited elevated 
CD4+ numbers in the urine. In contrast, patients with class I or pure class V nephritis showed 
only low numbers of urinary T cells (n = 3)  (Figure 3). 
In four SLE patients biopsied for suspected LN, the histology revealed a non SLE related 
kidney pathology. Two patients had a hypertensive nephropathy with CD4+ T cell counts of 20 
and 724/100ml. One patient had focal segmental glomerulosclerosis with urinary CD4+ T cell 
counts >1000/100ml. The fourth patient had minimal change nephropathy, which was considered 
by the treating clinicians as potentially SLE associated, with very few urinary T cells (Figure 3).  
 
Urinary CD4+ T cells are highly sensitive and specific in diagnosing inflammatory LN in 
SLE patients 
A receiver operator characteristic (ROC) curve was used to calculate the sensitivity and 
specificity to identify proliferative/inflammatory LN in SLE patients. This group contained all 20 
patients with biopsy proven proliferative LN, the two patients with biopsy showing atypical LN 
and four patients without current biopsy (n = 26). The non-inflammatory group contained all 
other SLE patients inclusive the patients with biopsy proven class I or V nephritis and the 
four SLE patients in whom biopsy indicated a non SLE related pathology (n=146). The area 
under the ROC curve (AUC) was 0.9969. A cut-off of 800 CD4+ T cells yielded a sensitivity 
of 100% and specificity of 98.0% to identify inflammatory LN in SLE patients (Figure 4). 
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In our cohort proteinuria and erythrocyte-/haemoglobinuria showed an inferior diagnostic 
performance than urinary T cells. The AUC for proteinuria to detect proliferative/inflammatory LN 
was 0.9123 and 0.8942 for erythrocyte-/haemoglobinuria. The respective AUC to indicate active 
LN was 0.9209 for proteinuria and 0,8788 for erythrocyte-/haemoglobinuria. Applying a cut-off of 
500mg/d proteinuria yields a sensitivity of 88.9% and specificity of 83.5% to detect active LN. 
The diagnostic performance of leucocytes in the urine and creatinine was even worse (AUC of 
0.5890 and 0.6281 detect active LN). 
 
Elevation of urinary CD4+ T cells is not a unique feature of LN 
Given the high diagnostic precision to identify inflammatory LN in SLE patients in our 
cohort, we determined whether elevation of urinary T cells is specific for LN compared with other 
kidney pathologies. A fraction of patients with diabetic nephropathy and ANCA associated 
vasculitis presented elevated numbers of urinary CD4+ T cells. In contrast, patients with 
proteinuric syndromes due to different aetiologies (minimal change glomerulonephritis, cast 
nephropathy and renal amyloidosis) showed no elevation of urinary T cells (Figure 5). 
 
Monitoring urinary CD4+ T cells indicates treatment response  
12 patients with acute LN (nine with biopsy proven class IV LN, one with biopsy proven 
extracapillary, proliferative necrotizing glomerulonephritis, two diagnosed without biopsy) were 
monitored under treatment. Of these 12 patients, 9 had normalized the amount of their urinary 
CD4+ T cells below the cut-off value of 800 cells/100ml urine within six months. These patients 
were considered “responders”. Three patients showed persistence of elevated amounts of 
urinary T cells >800/100ml despite six months of treatment. Two further patients who initially 
presented with normal urinary T cells counts were monitored and showed an increase of their 
urinary CD4+ T cells >800/100ml six months later. The patients that had not normalized or 
increased their urinary CD4+ T cells during the observation period were considered “non-
responders”. 
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Six months after the initial analysis the responders showed a significant reduction in their 
disease activity (initial median SLEDAI 16, six months later SLEDAI 2, p = 0.0006). The non-
responders showed no reduction in disease activity (initial median SLEDAI 12, six months later 
SLEDAI 12). Additionally, the responding group presented lower disease activity on month six 
than the non-responders (median SLEDAI 3 versus 12, p = 0.0141) (Figure 6A). The plasma 
creatinine levels were compared by calculating the creatinine at the six month visit as a 
percentage of the initial creatinine. The responders had lowered their creatinine levels (median 
73.55% of initial, 9/9 values available), which was significantly lower than the non-responding 
group (median 103.1% of initial, p = 0.0120, 5/5 values available) (Figure 6B). Similarly, the 
responders had a lower median proteinuria (percentage of the initial proteinuria, median 64.48%, 
6/9 values available) than the non-responders (median 104.4%, 5/5 values available); however 
this did not reach statistical significance (p = 0.1255) (Figure 6C). 
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Discussion 
In the present paper we report that urinary CD4+ T cells i) are elevated in SLE 
patients with active proliferative/inflammatory nephritis, ii) have an excellent sensitivity and 
specificity to identify proliferative nephritis in patients with SLE, and iii) can be used to 
monitor the treatment response of LN. In our study urinary CD4+ T cells >800/100ml 
identified SLE patients with active inflammatory nephritis. The high sensitivity and specificity 
to detect proliferative LN in patients with SLE is close to providing clinicians with a “black or 
white” performance of an optimal biomarker.  
In current clinical routine, SLE patients are mainly screened for renal involvement 
using creatinine, proteinuria and urinary sediment.[17] Although useful, these parameters have 
certain limitations. Creatinine and proteinuria can be persistently elevated and thereby 
unable to differentiate present kidney damage from acute nephritis. The sediment is 
potentially able to close this diagnostic gap; however it is only semi-quantitative and observer 
dependent. The mainstay for diagnosing LN is renal biopsy, which is not free of risk and is 
not suitable for monitoring the follow up. Furthermore, the interobserver agreement between 
renal pathologists classifying LN biopsies has recently been reported to be surprisingly low, 
including treatment relevant features such as grading a sample to be proliferative or not.[18] 
Several candidate urinary biomarkers have been published in recent years, most 
detected by ELISA or by RT-PCR (reviewed in [19-21]). Among the most promising novel 
biomarkers are molecules involved in the recruitment of cells into the kidney (chemokines 
and adhesion molecules) and molecules reflecting the renal inflammation (cytokines). 
Prominent examples are urinary MCP-1, VCAM-1, CXCL16 and TWEAK, which have all 
been reported in several independent publications.[22-26] However, the levels of these soluble 
urinary biomarkers show considerable overlap between SLE patients with active LN and 
those without active LN. Therefore, these molecules will be unable to clearly separate SLE 
patients with and without nephritis, limiting their clinical application. 
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Not surprisingly, elevated CD4+ T cells in the urine were not a unique finding in LN. 
Patients with other nephropathies that are known to be associated with an inflammatory 
infiltration also resulted in high urinary CD4+ T cell counts. This limitation is presumably 
shared by all urinary biomarkers reflecting the interstitial inflammation. Consequently, 
quantification of urinary T cells will not be helpful discriminating between lupus nephritis, 
ANCA vasculitis or another inflammatory nephropathy, but may be suitable to decide whether 
a SLE patient has active proliferative/inflammatory renal involvement or not. 
A cohort of patients was monitored for urinary CD4+ T cells in the follow up. Under 
treatment some patients normalized their urinary CD4+ T cells, while others showed 
persistence or even an increase. Similar observations of responders and non-responders 
were reported for urinary levels of MCP-1 and urinary mRNA levels of CXCL10, CXCR3, 
TGFbeta and VEGF.[23, 27] Here we were able to demonstrate that patients that had 
normalized their urinary CD4+ T cells within six months after diagnosis of nephritis had a 
better outcome than patients with persistence or increase of these cells. Interestingly three of 
the eight responders had normalized their urinary CD4+ T cell counts as early as 2-3 months 
after initiation of treatment, suggesting that monitoring urinary T cells may be predictive of 
the outcome. Moreover, it is reasonable to hypothesize that patients with persistence of 
urinary CD4+ T cells would benefit from more immunosuppression, while the treatment in 
patients with normalized cells may be reduced more rapidly. 
Flow cytometry of blood cells is routinely performed in most hospitals, so the 
requirements for quantification of urinary CD4+ T are widely available. Although CD4+ T cells 
have a limited survival in urine (82% die in 24h, data not shown), the survival over a time 
span of 4-6h was sufficient to detect the reported differences between patients with active 
and inactive LN. Furthermore in our data set neither urinary tract infections nor menstruation 
resulted in urinary CD4+ T cells numbers ≥ 800/100ml (data not shown).  Hence the 
quantification of urinary CD4+ T cells is an accessible technique with a robust readout that 
awaits to be exploited by the rheumatology and nephrology community. 
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Taken together, urinary CD4+ T cells represent a promising biomarker in the 
assessment of proliferative LN. Urinary CD4+ T cells may be used to monitor treatment 
response and enable a patient tailored treatment of LN in near future. Current limitations 
include the sparsity of data about non-proliferative forms of LN and lack of extensive data on 
follow up measurements. We hope that the current paper lays the basis for a large, multi-
center study on urinary CD4+ T cells as biomarker fur LN. 
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Figure 1. CD4+ T cells are found abundantly in the urine of patients with LN. A. 
Representative Dot-Plot showing CD3+CD4+ T cells in the urine of a patient with acute LN 
(gated on living lymphocytes). B. The amount of urinary CD4+ T cells correlates with the 
SLEDAI in SLE patients with renal involvement (filled circles, p < 0.0001, Spearman r = 
0.5987). In SLE patients without renal involvement very few urinary CD4+ T cells are 
detectable regardless of disease activity (open boxes, p = 0.2114, Spearman r = 0.2174). C. 
CD4+ T cell counts ≥800/100ml urine are exclusively found in SLE patients with active 
disease and renal involvement. D. The number of urinary CD4+ T cells in patients with active 
disease closely correlates with the rSLEDAI. 
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Figure 2. Correlation of the number of urinary CD4+ T cells with different markers for renal 
pathology. A. Urinary CD4+ T cells correlate with the plasma creatinine (p = 0.0007, 
Spearman r = 0.2685). B. Significant correlation between the amount of CD4+ T cells and 
proteins in the urine (p < 0.0001, Spearman r = 0.3883). C. Urinary CD4+ T cells and 
erythrocyte-/haemoglobinuria correlate (p < 0.0001, Spearman r = 0.5397). D. No correlation of 
urinary CD4+ T cells with leucocyteuria (p = 0.4468, Spearman r = 0.0629).  
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Figure 3. Results of concurrent kidney biopsies and number of urinary CD4+ T cells in 29 
patients. All patients with LN IV and atypical inflammatory LN have highly elevated urinary 
CD4+ T cell counts. No elevated urinary CD4+ counts in pure class I or V LN. 
 
 
 
Figure 4. Receiver operator characteristic (ROC) showing the diagnostic performance of urinary 
CD4+ T cells to detect proliferative/inflammatory LN in SLE patients. Area under the curve 
0.9969. Employing a cut-off of 800 CD4+ T cells yielded a sensitivity of 100% and specificity 
of 98.0%. 
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Figure 5. Elevated number of urinary CD4+ T cells is not a unique finding in LN. Patients 
with diabetic nephropathy and ANCA associated nephritis also present with elevated 
numbers of urinary CD4+ T cells.  
 
 
 
Figure 6. Follow up of patients under therapy. A. Patients who normalized their urinary 
CD4+ T cell counts <800/100ml within six months show a significant reduction of their 
SLEDAI. In contrast, patients with persistent or increased urinary CD4+ T cell numbers show 
no treatment response in their SLEDAI. B. Patients with normalized urinary CD4+ cells have 
significantly decreased creatinine levels then patients with increase or persistence of these 
cells (six month creatinine as % of initial creatinine). C. Higher proteinuria levels in patients 
with increase or persistence of their urinary CD4+ T cells, although not statistically significant 
(six month proteinuria as % of initial proteinuria). 
 
 
